PharmaVigilant Launches New User Interface for I-Warehouse
PharmaVigilant announced the availability of I-Warehouse 3.0, an enhanced version of the company’s unprecedented clinical data warehouse. The state-of-the-art system gives companies an innovative technology solution that provides immediate and ubiquitous access to study data with comparable results.
With I-Warehouse 3.0, the user interface has been redesigned to address the increasingly complex clinical trial environment. New features and functionality now streamline reporting to accommodate even more complex queries across multiple trials, and provides clients with access to their data at their fingertips. I-Warehouse offers superior organization of search criteria and a more streamlined selection process with drag and drop features, pre-populated mathematical calculations, and one-click results in the form of data on demand. Additionally, descriptive graphical summaries render visual components for study data results and report comparisons.
Additional features of I-Warehouse 3.0 include:
- Data on demand
- Import utility enabling competitive datasets to be incorporated into I-Warehouse
- Excel and PDF exports
- Customized charts and graphs
- Report regeneration
- Saved search criteria
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
